AGL 37.98 Increased By ▲ 0.48 (1.28%)
AIRLINK 220.50 Decreased By ▼ -2.39 (-1.07%)
BOP 10.95 Increased By ▲ 0.13 (1.2%)
CNERGY 7.40 Decreased By ▼ -0.16 (-2.12%)
DCL 9.20 Decreased By ▼ -0.22 (-2.34%)
DFML 40.80 Decreased By ▼ -0.16 (-0.39%)
DGKC 104.21 Decreased By ▼ -2.55 (-2.39%)
FCCL 36.05 Decreased By ▼ -1.02 (-2.75%)
FFL 19.40 Increased By ▲ 0.16 (0.83%)
HASCOL 12.95 Decreased By ▼ -0.23 (-1.75%)
HUBC 131.75 Decreased By ▼ -0.89 (-0.67%)
HUMNL 14.48 Decreased By ▼ -0.25 (-1.7%)
KEL 5.23 Decreased By ▼ -0.17 (-3.15%)
KOSM 7.50 Increased By ▲ 0.02 (0.27%)
MLCF 46.90 Decreased By ▼ -1.28 (-2.66%)
NBP 65.58 Decreased By ▼ -0.71 (-1.07%)
OGDC 220.40 Decreased By ▼ -2.86 (-1.28%)
PAEL 44.85 Increased By ▲ 1.35 (3.1%)
PIBTL 9.02 Decreased By ▼ -0.05 (-0.55%)
PPL 195.00 Decreased By ▼ -3.24 (-1.63%)
PRL 41.75 Decreased By ▼ -0.49 (-1.16%)
PTC 26.97 Decreased By ▼ -0.42 (-1.53%)
SEARL 109.00 Decreased By ▼ -1.08 (-0.98%)
TELE 10.39 Decreased By ▼ -0.13 (-1.24%)
TOMCL 36.24 Decreased By ▼ -0.38 (-1.04%)
TPLP 14.70 Decreased By ▼ -0.25 (-1.67%)
TREET 26.24 Decreased By ▼ -0.29 (-1.09%)
TRG 67.75 Decreased By ▼ -1.10 (-1.6%)
UNITY 33.50 Decreased By ▼ -0.69 (-2.02%)
WTL 1.75 Decreased By ▼ -0.04 (-2.23%)
BR100 12,344 Decreased By -19.3 (-0.16%)
BR30 37,784 Decreased By -434.4 (-1.14%)
KSE100 116,854 Decreased By -266 (-0.23%)
KSE30 36,852 Decreased By -85.1 (-0.23%)
Business & Finance

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

  • The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.
  • The company said it plans to publish data from its tests against the South African and U.K. variants on the website.
Published January 25, 2021

Moderna plans trial of altered COVID-19 vaccine booster to address South Africa variant

Moderna said on Monday it plans to start clinical trials of an altered booster version of its COVID-19 vaccine aimed at the South African variant after tests showed its authorised vaccine may produce a diminished antibody response.

It will also test an additional booster shot of its authorised vaccine in trials to see if it boosts antibody reaction against the South Africa variant. The current regimen is for two shots four weeks apart.

The company said in a press release that it was being cautious and that the two-dose regimen of the vaccine was still expected to be protective against the South African and other variants detected to date.

The company said the vaccine did not see any impact from the U.K. variant - which has been shown to be more transmissible - in the tests.

The company said it plans to publish data from its tests against the South African and U.K. variants on the website bioRxiv.

Comments

Comments are closed.